ArticleGut microbes2025
Engineered bacteria as an orally administered anti-viral treatment and immunization system.
Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Engineered bacterial therapeutics from synthetic biology to clinical translation: A multi-database scientometric analysis, 2000-2026.Human vaccines & immunotherapeutics · 2026Review
- Antibiotic Resistance and the Return to a Pre-Antibiotic Era: A Critical Narrative Review of a Global Catastrophe.Biomedicines · 2026Review
- Engineering commensal microbes for host health.Cell host & microbe · 2026Review
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- Therapeutic Efficacy of Multi-Characteristic Opsin Gene Therapy in a Mouse Model of Stargardt Disease.Bioengineering (Basel, Switzerland) · 2026Article
- Inhalable engineered probiotic outer membrane vesicles co-expressing multiple mpox antigens induce potent specific systemic and mucosal immune responses.Materials today. Bio · 2026Article
- Gut Microbiota: Cardiovascular Disease Prevention and Targeted Therapies.Biomedicines · 2026Review
- Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence.Viruses · 2026Review
- Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies.Biomedicines · 2026Review
- Engineered live bacteria for liver diseases and gut-liver axis disorders: from genetic modification to advanced delivery systems.Journal of nanobiotechnology · 2026Review
- Microbial medicines: Unlocking the therapeutic potential of the microbiome in cancer treatment.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Vitamin D3 contribution to systemic and local control ofFrontiers in molecular biosciences · 2026Article
- Integrated bioinformatics and mendelian randomization reveal a six-gene diagnostic signature and key role of CYP26B1 in sarcopenia.Frontiers in molecular biosciences · 2026Article
- Expression of immune-related genes and possible regulatory mechanisms in ulcerative colitis.Frontiers in molecular biosciences · 2026Article
- E3 ubiquitin ligases: structural diversity, dysregulation in disease, and their emerging role in targeted therapeutic strategies.Frontiers in molecular biosciences · 2026Review
- Differences in concentration of neuron-specific enolase (NSE), neutrophil elastase (NE), and calcium-binding protein S100B in viral diseases: a pilot study focused on normoglycemic COVID-19 patients.Frontiers in molecular biosciences · 2026Article
- Bacterial extracellular vesicles as multifaceted regulators of human diseases and emerging therapeutic platforms.Theranostics · 2026Review
- Deciphering the association between dietary live microbe intake and metabolic syndrome: exploring the effects of inflammation and insulin resistance.Journal of health, population, and nutrition · 2025Article
- Exploring the Role of Transcriptomics, Proteomics, and Machine Learning in HPV Infection and Cardiovascular Disease.Biomedicines · 2025Review
- Genetically Engineered Probiotics: Design, Therapeutics, and Clinical Translation.Iranian biomedical journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The emergence of new viral pathogens necessitates innovative antiviral therapies and vaccines. Traditional approaches, such as monoclonal antibodies and vaccines, are often hindered by resistance, limited effectiveness, and high costs. Here, we develop an engineered probiotic-based antiviral platform using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.